BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 364 filers reported holding BIO-TECHNE CORP in Q2 2019. The put-call ratio across all filers is 7.53 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,098,457 | -16.6% | 148,354 | -0.0% | 0.03% | -12.5% |
| Q2 2023 | $12,114,545 | +18.8% | 148,408 | +8.0% | 0.03% | +28.0% |
| Q1 2023 | $10,194,596 | +78217.6% | 137,412 | -12.5% | 0.02% | -26.5% |
| Q4 2022 | $13,017 | -99.9% | 157,059 | +321.3% | 0.03% | +9.7% |
| Q3 2022 | $10,589,000 | -12.3% | 37,283 | +7.0% | 0.03% | -8.8% |
| Q2 2022 | $12,079,000 | -18.2% | 34,845 | +2.1% | 0.03% | -8.1% |
| Q1 2022 | $14,773,000 | -19.1% | 34,114 | -3.4% | 0.04% | -14.0% |
| Q4 2021 | $18,270,000 | +17.8% | 35,316 | +10.3% | 0.04% | +7.5% |
| Q3 2021 | $15,514,000 | +27.8% | 32,016 | +18.8% | 0.04% | +25.0% |
| Q2 2021 | $12,136,000 | +19.1% | 26,954 | +1.0% | 0.03% | +10.3% |
| Q1 2021 | $10,189,000 | +18.1% | 26,678 | -1.8% | 0.03% | +11.5% |
| Q4 2020 | $8,624,000 | +30.9% | 27,159 | +2.1% | 0.03% | +13.0% |
| Q3 2020 | $6,588,000 | +9.4% | 26,595 | +16.6% | 0.02% | 0.0% |
| Q2 2020 | $6,021,000 | +41.9% | 22,799 | +1.9% | 0.02% | +21.1% |
| Q1 2020 | $4,243,000 | -11.1% | 22,378 | +2.9% | 0.02% | +11.8% |
| Q4 2019 | $4,773,000 | +13.6% | 21,746 | +1.2% | 0.02% | 0.0% |
| Q3 2019 | $4,203,000 | -4.4% | 21,481 | +1.9% | 0.02% | 0.0% |
| Q2 2019 | $4,397,000 | +6.5% | 21,090 | +1.4% | 0.02% | -29.2% |
| Q1 2019 | $4,129,000 | +679.1% | 20,794 | +467.4% | 0.02% | +500.0% |
| Q4 2018 | $530,000 | -34.5% | 3,665 | -7.7% | 0.00% | -20.0% |
| Q3 2018 | $809,000 | +34.2% | 3,971 | -2.6% | 0.01% | +25.0% |
| Q2 2018 | $603,000 | +4.1% | 4,077 | +6.3% | 0.00% | 0.0% |
| Q1 2018 | $579,000 | -6.3% | 3,836 | -19.6% | 0.00% | 0.0% |
| Q4 2017 | $618,000 | -17.2% | 4,771 | -22.7% | 0.00% | -33.3% |
| Q3 2017 | $746,000 | +20.7% | 6,171 | +17.3% | 0.01% | +20.0% |
| Q2 2017 | $618,000 | +21.7% | 5,262 | +5.3% | 0.01% | +25.0% |
| Q1 2017 | $508,000 | -2.5% | 4,997 | -1.3% | 0.00% | -20.0% |
| Q4 2016 | $521,000 | -6.5% | 5,062 | -0.5% | 0.01% | 0.0% |
| Q3 2016 | $557,000 | -3.0% | 5,087 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $574,000 | +15.0% | 5,087 | -3.7% | 0.01% | 0.0% |
| Q1 2016 | $499,000 | +18.8% | 5,282 | +13.1% | 0.01% | +25.0% |
| Q4 2015 | $420,000 | -3.9% | 4,672 | -1.0% | 0.00% | -20.0% |
| Q3 2015 | $437,000 | -8.4% | 4,721 | -2.6% | 0.01% | 0.0% |
| Q2 2015 | $477,000 | – | 4,846 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |